Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test

Transgenomics' CEO said these first forays into next-gen sequencing don't represent a shift in the company's strategy, which has so far been focused on Sanger sequencing and PCR technologies for molecular diagnostics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.